Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1417254 | 0.71 | ALDH1A1 (0.39) | CYP2A6POLBALOX12KDM4EALDH1A1 | |
| SCHEMBL3500419 | 0.68 | CYP2A6 (0.36) | CYP2A6POLBALOX12KDM4EALDH1A1 | |
| SCHEMBL4427042 | 0.67 | SRC (0.47) | CYP2A6POLBALOX12KDM4EALDH1A1 | |
| SCHEMBL2222194 | 0.66 | — | — | |
| SCHEMBL17398210 | 0.64 | CYP2A6 (0.39) | CYP2A6POLBALOX12KDM4EALDH1A1 | |
| SCHEMBL3500260 | 0.64 | POLB (0.35) | CYP2A6POLBALOX12KDM4EALDH1A1 | |
| SCHEMBL1199234 | 0.63 | — | — | |
| SCHEMBL12060697 | 0.63 | — | — | |
| SCHEMBL8425449 | 0.63 | — | — | |
| SCHEMBL15268303 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492405-B2 | Glucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-23 | — | — | US | disclosed |
| US-20100184794-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-22 | — | — | US | disclosed |
| EP-2077267-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184794-A1 | FUSED HETEROCYCLIC COMPOUND | GCKR, GCK, SLC5A1 | CYP2A6 470/4885POLB 4001/4885ALOX12 3252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.